Clinical Trial

A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is to explore the the reasonable dosage and to evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in combination with Serplulimab (anti-PD-1 humanized monoclonal antibody injection) in patients with advanced lung cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-11-19; most recent amendment 2026-07-20.
Status change: Not Yet Recruiting → Recruiting 2026-07-20
Trial Details
NCT Number NCT07253142
Lead Sponsor Shanghai Henlius Biotech
Conditions Non Small Cell Lung Cancer, Small Cell Lung Cancer
Enrollment 120 participants
Start Date 2026-02-05
Primary Completion 2027-06-18 (estimated)
Study Completion 2028-06-19 (estimated)
Updated on ClinicalTrials.gov 2026-07-21